Decreased levels of regulatory B cells in patients with systemic sclerosis: Association with autoantibody production and disease activity

Rheumatology (United Kingdom)

Volumn 55, Issue 2, 2015, Pages 263-267

  Matsushita, Takashi ^a   Hamaguchi, Yasuhito ^a   Hasegawa, Minoru ^b   Takehara, Kazuhiko ^a   Fujimoto, Manabu ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

IL 10; Regulatory B cell; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CD24 ANTIGEN; CD27 ANTIGEN; CENTROMERE ANTIBODY; INTERLEUKIN 10;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 84961933324     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev331     Document Type: Article

References (19)

1. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-27.
3. Matsushita T, Fujimoto M, Hasegawa M et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007;127:2772-80.
4. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-66.
5. McQueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology 2015;54:757-67.
6. Le Huu D, Matsushita T, Jin G et al. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood 2013;121:3274-83.
7. Iwata Y, Matsushita T, Horikawa M et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117:530-41.
8. Blair PA, Norena LY, Flores-Borja F et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010;32:129-40.
9. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-8.
10. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
11. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Eng J Med 1975;292:344-8.
13. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
14. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 2001;40:1135-40.
15. Chizzolini C. T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999;21:431-50.
16. Fujimoto M. Regulatory B cells in skin and connective tissue diseases. J Dermatol Sci 2010;60:1-7.
17. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-30.
18. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
19. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.